3rd Immunotherapy of Cancer Conference (ITOC3)

Immunology highlights from the ITOC-3 conference

Prof Heinz Zwierzina - Innsbruck University, Innsbruck, Austria

12 Apr 2016

Novel technologies for understanding the repertoire of tumour infiltrating T cells in cancer

Prof Sine Reker Hadrup - Technical University of Denmark, Kongens Lyngby, Denmark

7 Apr 2016

Targeting AFP in hepatocellular cancer

Dr Lisa Butterfield University of Pittsburgh, Pittsburgh, USA

5 Apr 2016

Combination of viroimmunotherapy with checkpoint inhibitors

Prof Alan Melcher - The Institute of Cancer Research and The Royal Marsden Hospital, London, UK

4 Apr 2016

Is PD-L1 really a predictive biomarker?

Dr Paolo Ascierto - National Tumor Institute, Naples, Italy

4 Apr 2016

Patient perspective on immunotherapy and the ITOC-3 conference

Peter Trayhurn - Patient advocate

4 Apr 2016

Hypoxia and its impact on the immune system

Dr Luigi Varesio - Giannina Gaslini Institute, Genova, Italy

4 Apr 2016

The role of microRNAs in modulation of the immune escape of tumors

Dr Barbara Seliger - Universitätsklinikum Halle , Saale, Germany

4 Apr 2016

Reprogramming the cancer microenvironment with vaccine-based therapy

Prof Lei Zheng - John Hopkins Institute Baltimore, USA

4 Apr 2016

T cells expressing two additional receptors (TETARs) for the use in a multiple- hit immunotherapy

Dr Gerold Schuler - Universitätsklinikum, Erlangen, Germany

4 Apr 2016

Biomarkers in t-cell therapy trials

Dr Jérôme Galon - Laboratory of Integrative Cancer Immunology, Paris, France

4 Apr 2016

Immunotherapy and personalised medicine in review

Prof Paul Sondel - University of Wisconsin, Madison, USA

4 Apr 2016

Rationale for combining immunotherapy with chemotherapy

Prof Angus Dalgleish - St. Georges University, London UK

1 Apr 2016

Targeting tumour vasculature by DNA vaccines

Dr Andrea Facciabene - University of Pennsylvania, Philadelphia, USA

1 Apr 2016

Conferences